Role of omalizumab in insulin hypersensitivity: a case report and review of the literature
ConclusionTo our knowledge, this is the first described case of allergy to insulin glargine 300 units/ml and reiterates the potential use of omalizumab in insulin allergy. Further research is warranted to determine if omalizumab should be considered standard of care in difficult‐to‐treat insulin hypersensitivity.This article is protected by copyright. All rights reserved. (Source: Diabetic Medicine)
Source: Diabetic Medicine - January 30, 2018 Category: Endocrinology Authors: S. Mishra, L. Connors, B. Tugwell Tags: Case Report Source Type: research
Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes.
CONCLUSION: Despite improving beta-cell function, insulin resistance and glucagonemia, short-term IIT does not change GLP-1 secretion and decreases the GIP response to an oral glucose challenge in early type 2 diabetes. Thus, the beneficial impact of this therapy on glucose homeostasis is not attributable to its effects on incretin secretion.
PMID: 29395808 [PubMed - as supplied by publisher] (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - January 11, 2018 Category: Endocrinology Authors: Choi H, Kramer CK, Zinman B, W Connelly P, Retnakaran R Tags: Diabetes Metab Source Type: research
Efficacy and safety of fast ‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52‐week, randomized, treat‐to‐target, phase 3 trial
ConclusionsAt 52 weeks, overall glycaemic control had significantly improved with faster aspart versus IAsp, consistent with the 26‐week study findings. Achieving an insulin profile closer to physiological insulin secretion with faster aspart translates into lower PPG and HbA1c levels in subjects with T1D compared with IAsp. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - January 8, 2018 Category: Endocrinology Authors: Chantal Mathieu, Bruce W. Bode, Edward Franek, Athena Philis ‐Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell‐Jones Tags: ORIGINAL ARTICLE Source Type: research
Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin
This study examines the relationship between glycated hemoglobin (A1C) levels and treatment persistence with, or time to discontinuation of, basal insulin in patients with type 2 diabetes (T2D) newly initiating insulin. Claims data were extracted from the Optum™ Clinformatics database from January 2010 to June 2015. Adult patients with T2D initiating insulin glargine 100 U/mL (Gla‐100) or insulin detemir (DET) with ≥1 A1C measurement during 12‐month baseline and 18‐month follow‐up periods were included. Patients with a refill gap of >90 days were considered non‐persistent; otherwise patients were considere...
Source: Diabetes, Obesity and Metabolism - December 26, 2017 Category: Endocrinology Authors: Fang Liz Zhou, Lin Xie, Chunshen Pan, Yuexi Wang, Neel Vaidya, Fen Ye, Ronald Preblick, Luigi Meneghini Tags: BRIEF REPORT Source Type: research
The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
Type II diabetes is an important health problem with a complex connection to obesity, leading to a broad range of cardiovascular complications. Insulin therapy often results in weight gain and does not always ... (Source: Diabetology and Metabolic Syndrome)
Source: Diabetology and Metabolic Syndrome - December 4, 2017 Category: Endocrinology Authors: Tomislav Bozek, Antonela Blazekovic, Matea Nikolac Perkovic, Kristina Gotovac Jercic, Aleksandra Sustar, Lea Smircic-Duvnjak, Tiago F. Outeiro, Nela Pivac and Fran Borovecki Tags: Research Source Type: research
Central effects of insulin detemir on feeding, body weight, and metabolism in rats
Insulin detemir (DET) is a basal insulin analog that, in contrast to other long-acting forms of insulin, has significant weight-gain-sparing effects in diabetic patients. We hypothesized that this effect of DET may be due to its enhanced catabolic action in the central nervous system. We investigated the long-term effects of single third ventricular (3V) microinjections of equimolar doses of DET and regular insulin in normal male rats on feeding, body weight, energy expenditure (EE), and respiratory quotient (RQ). Also, in acute testing, we assessed the ability of lower doses of DET to alter feeding, EE, and RQ when microi...
Source: AJP: Endocrinology and Metabolism - November 29, 2017 Category: Endocrinology Authors: Vasselli, J. R., Pi-Sunyer, F. X., Wall, D. G., John, C. S., Chapman, C. D., Currie, P. J. Tags: Research Article Source Type: research
Astragaloside IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocin ‑induced diabetic rat model.
Astragaloside IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocin‑induced diabetic rat model.
Int J Mol Med. 2017 Nov 17;:
Authors: He KQ, Li WZ, Chai XQ, Yin YY, Jiang Y, Li WP
Abstract
Diabetic patients are able to manage their blood glucose with exogenous insulin but, ultimately, remain at risk of diabetic nephropathy (DN). Long‑term use of insulin may lead to iatrogenic hyperinsulinemia, which has been suggested to cause kidney injury. However, there are no effective interventions for iatrogenic hyperinsulinemia leading to kidney damage. In ...
Source: International Journal of Molecular Medicine - November 17, 2017 Category: Molecular Biology Authors: He KQ, Li WZ, Chai XQ, Yin YY, Jiang Y, Li WP Tags: Int J Mol Med Source Type: research
Biphasic insulin aspart ‐30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once‐daily insulin regimens using continuous glucose monitoring
Journal of Diabetes Investigation,Volume 9, Issue 3, Page 573-578, May 2018. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - October 27, 2017 Category: Endocrinology Authors: Daisuke Tsujino
,
Rimei Nishimura
,
Yoshiko Onda
,
Chiaki Seo
,
Kiyotaka Ando
,
Kazunori Utsunomiya Source Type: research
Impact of Insulin Detemir Administration Time on Hypoglycemia Rates in Hospitalized Patients
ConclusionAdministration of detemir in the morning may reduce the occurrence of hypoglycemia in hospitalized patients. Institutions that include detemir on their formularies may consider evaluating the incidence of hypoglycemia and modifying administration schedules as part of their medication safety program.This article is protected by copyright. All rights reserved. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 13, 2017 Category: Drugs & Pharmacology Authors: Jennifer L. Grelle, Sydney N. Kutter, Megan E. Giruzzi, John C. Tawwater Tags: Original Research Article Source Type: research
Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
CONCLUSIONS: Initiating insulin treatment with detemir, but not with glargine, was associated with a significantly lower risk of severe hypoglycemia compared to NPH, among working-age adults. KEY MESSAGES The comparative safety of modern basal insulins regarding hypoglycemia among the working-age population is unclear. Large reductions in the incidence of severe hypoglycemia were seen among real-life patients who started insulin detemir, as compared to patients who initiated glargine or especially NPH insulin. Given the large amount of patients using insulin, these findings may have considerable clinical consequences at th...
Source: Annals of Medicine - October 12, 2017 Category: Internal Medicine Tags: Ann Med Source Type: research
Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials
ConclusionsFor patients with high HbA1c, treatment with exenatide or insulin both improved glycaemic control. Given the associated weight loss and low risk of hypoglycaemia, exenatide may be a suitable alternative to treatment with insulin in certain patients with T2D and high HbA1c. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - October 1, 2017 Category: Internal Medicine Authors: Robert S. Busch, James Ruggles, Jenny Han, Elise Hardy Tags: ORIGINAL PAPER Source Type: research
Biphasic insulin aspart ‐30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once‐daily insulin regimens using continuous glucose monitoring
ConclusionAs once‐daily insulin injection therapy given before breakfast in type 2 diabetes, the biphasic insulin analogue may represent a better insulin option in significantly lowering %CV and MAGE than the long‐acting insulin preparation.This article is protected by copyright. All rights reserved. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - September 16, 2017 Category: Endocrinology Authors: Daisuke Tsujino, Rimei Nishimura, Yoshiko Onda, Chiaki Seo, Kiyotaka Ando, Kazunori Utsunomiya Tags: Clinical Trial Source Type: research
Molecules, Vol. 22, Pages 1274: Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir
Krystyna Olczyk
The aim of the present study is to quantitatively assess the expression of selected regulatory molecules, such as leptin, leptin receptor, and adiponectin in the blood of obese patients with type 2 diabetes both before treatment and after six months of pharmacological therapy with the long-lasting insulin analogue, insulin detemir. A significant decrease in the analysed regulatory molecules, i.e., leptin receptor and adiponectin, was found in blood plasma of the patients with untreated type 2 diabetes. These changes were accompanied by an increase in plasma leptin concentrations. Insulin treatment resu...
Source: Molecules - July 30, 2017 Category: Chemistry Authors: Pawe ł Olczyk Robert Koprowski Katarzyna Komosinska-Vassev Agnieszka Jura-P ółtorak Katarzyna Winsz-Szczotka Kornelia Ku źnik-Trocha Łukasz Mencner Alicja Telega Diana Ivanova Krystyna Olczyk Tags: Article Source Type: research
Central Effects of Insulin Detemir on Feeding, Body Weight and Metabolism in Rats.
Abstract
Insulin detemir (DET) is a basal insulin analog that, in contrast to other long-acting forms of insulin, has significant weight-gain sparing effects in diabetic patients. We hypothesized that this effect of DET may be due to its enhanced catabolic action in the CNS. We investigated the long-term effects of single third ventricular (3V) microinjections of equimolar doses of DET and regular insulin in normal male rats on feeding, body weight, energy expenditure (EE) and respiratory quotient (RQ). Also in acute testing, we assessed the ability of lower doses of DET to alter feeding, EE and RQ when mi...
Source: American Journal of Physiology. Endocrinology and Metabolism - July 18, 2017 Category: Physiology Authors: Vasselli JR, Pi-Sunyer FX, Wall DG, John CS, Chapman CD, Currie PJ Tags: Am J Physiol Endocrinol Metab Source Type: research
Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from payer's perspective.
CONCLUSIONS: Treatment with IDet in patients with T2DM who had uncontrolled blood glucose with oral anti-diabetic agents was not a cost-effective strategy compared with IGlar treatment in Thai context. Our findings could be generalized to other countries with similar socioeconomics level and health care systems.
PMID: 28649943 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - June 28, 2017 Category: Health Management Tags: J Med Econ Source Type: research
